Trivium Point Advisory’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-34,397
Closed -$996K – 272
2025
Q4
$996K Sell
34,397
-3,172
-8% -$95.2K 0.1% 179
2025
Q3
$1.04M Buy
+37,569
New +$949K 0.11% 176

Other funds holding ARKG

Trivium Point Advisory's ARKG Position: Q1 2026 in Review

Trivium Point Advisory sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2026, closing a stake of 34,397 shares — an estimated $996K sold.

Trivium Point Advisory first reported a position in ARKG in Q3 2025 and held it in 2 quarters. The position peaked at $1.04M in Q3 2025. 220 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • Trivium Point Advisory reported no remaining ARK Genomic Revolution ETF position as of Q1 2026 after selling out during the quarter.
  • Trivium Point Advisory sold 34,397 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $996K.
  • Trivium Point Advisory first reported a position in ARK Genomic Revolution ETF in Q3 2025 and held it in 2 quarters.
  • Trivium Point Advisory's ARK Genomic Revolution ETF position peaked at $1.04M in Q3 2025.
  • 220 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Trivium Point Advisory's 13F filing for Q1 2026, filed 21 Apr 2026.